The effect of non-insulin-dependent diabetes mellitus and obesity on glucose transport and phosphorylation in skeletal muscle

D E Kelley, M A Mintun, S C Watkins, J A Simoneau, F Jadali, A Fredrickson, J Beattie, R Thériault, D E Kelley, M A Mintun, S C Watkins, J A Simoneau, F Jadali, A Fredrickson, J Beattie, R Thériault

Abstract

Defects of glucose transport and phosphorylation may underlie insulin resistance in obesity and non-insulin-dependent diabetes mellitus (NIDDM). To test this hypothesis, dynamic imaging of 18F-2-deoxy-glucose uptake into midthigh muscle was performed using positron emission tomography during basal and insulin-stimulated conditions (40 mU/m2 per min), in eight lean nondiabetic, eight obese nondiabetic, and eight obese subjects with NIDDM. In additional studies, vastus lateralis muscle was obtained by percutaneous biopsy during basal and insulin-stimulated conditions for assay of hexokinase and citrate synthase, and for immunohistochemical labeling of Glut 4. Quantitative confocal laser scanning microscopy was used to ascertain Glut 4 at the sarcolemma as an index of insulin-regulated translocation. In lean individuals, insulin stimulated a 10-fold increase of 2-deoxy-2[18F]fluoro-D-glucose (FDG) clearance into muscle and significant increases in the rate constants for inward transport and phosphorylation of FDG. In obese individuals, the rate constant for inward transport of glucose was not increased by insulin infusion and did not differ from values in NIDDM. Insulin stimulation of the rate constant for glucose phosphorylation was similar in obese and lean subjects but reduced in NIDDM. Insulin increased by nearly twofold the number and area of sites labeling for Glut 4 at the sarcolemma in lean volunteers, but in obese and NIDDM subjects translocation of Glut 4 was attenuated. Activities of skeletal muscle HK I and II were similar in lean, obese and NIDDM subjects. These in vivo and ex vivo assessments indicate that impaired glucose transport plays a key role in insulin resistance of NIDDM and obesity and that an additional impairment of glucose phosphorylation is evident in the insulin resistance of NIDDM.

References

    1. Diabetes. 1995 Mar;44(3):330-4
    1. J Clin Invest. 1987 Aug;80(2):415-24
    1. Diabetes. 1995 Mar;44(3):347-53
    1. J Nucl Med. 1995 Mar;36(3):456-63
    1. J Clin Invest. 1995 Apr;95(4):1846-53
    1. Am J Physiol. 1995 Apr;268(4 Pt 1):E613-22
    1. FASEB J. 1995 Feb;9(2):273-8
    1. Am J Physiol. 1995 Jul;269(1 Pt 1):E150-4
    1. J Clin Invest. 1995 Aug;96(2):1003-9
    1. J Biol Chem. 1970 Aug 25;245(16):4081-96
    1. J Clin Invest. 1988 May;81(5):1528-36
    1. Diabetes. 1988 Jul;37(7):885-90
    1. Diabetes. 1988 Aug;37(8):1025-34
    1. J Clin Invest. 1988 Aug;82(2):486-94
    1. Am J Physiol. 1988 Sep;255(3 Pt 1):E374-82
    1. Am J Physiol. 1988 Dec;255(6 Pt 1):E942-5
    1. N Engl J Med. 1990 Jan 25;322(4):223-8
    1. Diabetes Care. 1990 Mar;13(3):198-208
    1. Diabetes Care. 1990 Mar;13(3):228-43
    1. Int J Sports Med. 1990 Feb;11 Suppl 1:S10-4
    1. J Clin Invest. 1990 Jun;85(6):1844-52
    1. Diabetes. 1990 Jul;39(7):865-70
    1. Am J Physiol. 1990 Jun;258(6 Pt 1):E923-9
    1. Diabetes. 1990 Nov;39(11):1373-80
    1. J Clin Invest. 1990 Dec;86(6):1999-2007
    1. Rev Physiol Biochem Pharmacol. 1990;116:1-76
    1. Am J Physiol. 1991 Mar;260(3 Pt 1):C570-80
    1. Diabetes. 1991 Dec;40(12):1712-8
    1. Hum Genet. 1992 Mar;88(5):557-61
    1. J Biol Chem. 1992 Mar 25;267(9):6278-85
    1. J Clin Invest. 1992 Apr;89(4):1069-75
    1. J Clin Invest. 1992 May;89(5):1367-74
    1. J Clin Invest. 1992 Jun;89(6):1767-74
    1. Diabetes. 1992 Apr;41(4):465-75
    1. J Nucl Med. 1992 Aug;33(8):1523-9
    1. Diabetes. 1993 Jan;42(1):191-8
    1. J Clin Invest. 1993 May;91(5):1897-902
    1. J Clin Invest. 1993 Jul;92(1):486-94
    1. J Nucl Med. 1993 Dec;34(12):2064-7
    1. Eur J Biochem. 1994 Jan 15;219(1-2):307-15
    1. J Appl Physiol (1985). 1994 Feb;76(2):979-85
    1. J Biol Chem. 1994 Apr 29;269(17):12963-7
    1. Am J Physiol. 1994 Apr;266(4 Pt 1):E548-59
    1. Acta Physiol Scand. 1994 Aug;151(4):527-30
    1. J Clin Invest. 1994 Dec;94(6):2349-56
    1. Circulation. 1994 Dec;90(6):2629-34
    1. Diabetes. 1995 Jan;44(1):31-6
    1. J Neurochem. 1977 May;28(5):897-916
    1. Am J Physiol. 1979 Sep;237(3):E214-23
    1. Ann Neurol. 1979 Nov;6(5):371-88
    1. Med Sci Sports Exerc. 1982;14(1):101-2
    1. J Cereb Blood Flow Metab. 1985 Jun;5(2):179-92
    1. J Nucl Med. 1986 Feb;27(2):235-8
    1. Int J Rad Appl Instrum A. 1986;37(8):663-8
    1. FEBS Lett. 1987 May 25;216(1):128-32
    1. Diabetes. 1995 Mar;44(3):340-6

Source: PubMed

Подписаться